Skip to main content

Find Clinical Trials

Home
Conditions
Hepatitis B, Chronic

Clinical trial condition

Hepatitis B, Chronic

Explore clinical trials studying Hepatitis B, Chronic. Study availability and eligibility vary by location and protocol.

162 public trials 12 recruiting studies

Refine in advanced search Browse all conditions

Hepatitis B, Chronic trial results

Completed

A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B

NCT00436163

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Tallinn, Estonia

Tallinn, Estonia

Tartu, Estonia

Riga, Latvia

View Trial Details

Completed

Lamivudine(LAM) Good Responder Study

NCT01128686

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: GSK Investigational Site Kangwon-do, South Korea

View Trial Details

Completed

Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue

NCT01480284

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: GSK Investigational Site Aichi, Japan

GSK Investigational Site Aichi, Japan

GSK Investigational Site Chiba, Japan

GSK Investigational Site Fukui, Japan

View all 32 locations

View Trial Details

Completed

An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B

NCT01787279

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Casablanca, Morocco

Casablanca, Morocco

Rabat, Morocco

Rabat, Morocco

View Trial Details

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.

NCT01519921

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Busan, South Korea

Daegu, South Korea

Seoul, South Korea

Seoul, South Korea

View Trial Details

Completed

A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B

NCT00940485

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Changsha, China

Chengdu, China

Fuzhou, China

Guangzhou, China

View Trial Details

Completed

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

NCT00927082

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Fitzroy, Victoria, Australia

Salvador, Estado de Bahia, Brazil

Campinas, São Paulo, Brazil

Ribeirão Preto, São Paulo, Brazil

View all 31 locations

View Trial Details

Completed

A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both

NCT00962871

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Los Angeles, California, United States

San Francisco, California, United States

Grafton, New Zealand

Singapore

View Trial Details

Completed

A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B

NCT02598063

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Beijing, China

Beijing, China

Beijing, China

Chongqing, China

View Trial Details

Completed

Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients

NCT02646163

Conditions: Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations: Farabi General Hospital Dhaka, Bangladesh

View Trial Details